HER2

Breaking Through the Treatment Dilemma of Advanced Ovarian Cancer: Precision Exploration from FRα to HER2

by
Breaking Through the Treatment Dilemma of Advanced Ovarian Cancer: Precision Exploration from FRα to HER2

Introduction Ovarian cancer is one of the most common malignant tumors in gynecology, with the highest mortality rate among gynecological malignancies. Despite continuous advancements in clinical surgery and ongoing optimization of chemotherapy regimens, the prognosis for patients with advanced ovarian cancer remains poor, especially for those who are resistant to platinum-based drugs, leaving limited treatment … Read more

The αC-β4 Loop Structure of HER2 in Lung Cancer: Decoding the Key to Overcoming Resistance in Targeted Therapy

by
The αC-β4 Loop Structure of HER2 in Lung Cancer: Decoding the Key to Overcoming Resistance in Targeted Therapy

Abstract National Natural Science Foundation Project Report HER2 exon 20 insertion mutations (HER2 20ins) are the most common type of HER2 mutations in lung cancer, accounting for 62%-90%. However, the response rate of these patients to existing targeted drugs (such as TKIs) is only 10%-30%, and the mechanisms of resistance have long been unclear. The … Read more

Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

by
Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more

The Development History of ADC Over 40 Years (Part 3)

by
The Development History of ADC Over 40 Years (Part 3)

The Metabolism Process of ADC The in vivo delivery process of the payload is complicated due to the complex structure of ADCs and their metabolic degradation in the body. After ADC administration, the Drug-to-Antibody Ratio (DAR), bound or free antibodies, albumin conjugates, free payloads, and payload metabolites are all in a highly dynamic state over … Read more

ERICA Study: Preventing Nausea and Vomiting Associated with Novel HER2 ADC Treatment

by
ERICA Study: Preventing Nausea and Vomiting Associated with Novel HER2 ADC Treatment

Click the blue text above to follow us Editor’s Note: Novel HER2 antibody-drug conjugates (ADCs) have profoundly changed the clinical practice of breast cancer treatment, and managing their adverse reactions is a concern for clinicians. Although nausea and vomiting caused by novel HER2 ADCs in clinical trials are mostly mild adverse events, current international guidelines … Read more

New Hope for Solid Tumors! DS-8201 Achieves Over 22 Months of Sustained Relief and Receives Two Breakthrough Therapy Designations

by
New Hope for Solid Tumors! DS-8201 Achieves Over 22 Months of Sustained Relief and Receives Two Breakthrough Therapy Designations

Since the emergence of several new drugs for the treatment of solid tumors, such as larotrectinib and entrectinib, the concept of “broad-spectrum anti-cancer drugs” has officially entered public awareness. Years later, more and more broad-spectrum anti-cancer drugs have moved from the laboratory to clinical settings, officially ushering in this precise yet “broad-spectrum” era of cancer … Read more

ADC Drug Advances in Non-Small Cell Lung Cancer

by
ADC Drug Advances in Non-Small Cell Lung Cancer

Introduction Despite rapid advancements in targeted therapy for NSCLC (non-small cell lung cancer), there remains an unmet need. This article summarizes the latest progress in targeted therapies for NSCLC involving Her2, Her3, and Trop-2 to inform readers. NSCLC and ADC Whether through targeted therapy or immunotherapy, the number of lung cancer patients benefiting remains limited, … Read more

The Arrival of Quadruple Antibody-Drug Conjugates (ADCs)

by
The Arrival of Quadruple Antibody-Drug Conjugates (ADCs)

The development of next-generation ADC drugs has gradually shifted towards the development of new toxins and linkers as foundational technologies. Multi-antibody or multi-toxin approaches have become a new trend. Following Araris and Puzhong’s advancements in tri-toxin and hexatozin,Aarvik has now introduced quadruple antibody-drug conjugates (ADCs). Aarvik may not have a prominent reputation in the ADC … Read more

ADC Drugs: The ‘Magic Bullets’ for Cancer Treatment

by
ADC Drugs: The 'Magic Bullets' for Cancer Treatment

1. Overview of ADC Drugs Antibody-drug conjugates (ADCs) are referred to as the ‘magic bullets’ for cancer treatment. They are a new type of biotherapeutic drug that combines monoclonal antibodies with cytotoxic drugs through a chemical linker. The core concept is to combine the specific targeting ability of antibodies with the powerful killing effect of … Read more

Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

by
Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

Introduction The DS8201-A-U105 study reveals the latest advancements in ADC combined immunotherapy. What insights can we draw from it? The annual European Society for Medical Oncology Breast Cancer (ESMO BC) conference was officially held from May 3-5, 2022, reporting a series of significant advancements in the field of breast cancer. ADCs have become star drugs … Read more